You are here

Manufacturing medicines in Australia: examining the need for increased domestic capability

26 May 2020 | Australia
Legal Briefings – By Shaun McVicar and Emma Iles

Share

There has been much discussion about the need for Australia to increase “sovereign capability” in domestic pharmaceutical manufacturing. 

 

 

 

Against an international backdrop this article discusses the identified supply chain risks and considers whether such an initiative is commercially feasible in the absence of significant government investment and intervention. It also looks at two key initiatives already in place designed to help mitigate the risk of medicine supply chain shortages.

See how we help our clients in

Pharmaceuticals and Healthcare

Learn More

Key Contacts